Jawad Kadhum Muraih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jawad Kadhum Muraih has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jared Silverman
Cubist Pharmaceuticals, Lexington, MA, USA
4 shared publicationsMichael Palmer
4 shared publicationsTianHua Zhang
Department of Chemistry, University of Waterloo, Waterloo N2L 3G1, Ontario, Canada
4 shared publicationsEvan Mintzer
Department of Chemistry and Physics, Lander College of Arts and Sciences, Touro College, 1602 Ave. J, Brooklyn, NY 11230, United States
3 shared publications- Michael Palmer
Department of Chemistry, University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada
3 shared publications Nasim Tishbi
‖Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421
2 shared publications
Latest Publications
- Open Access
- 20 February 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (1) , 461-468
The Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection
Background: IL-6 is one of the most studied cytokines in kidney disease. It is making inflammation worse by activating B cells that affect the production of hepatic acute phase proteins. It is also involved in metabolic, regenerative, and neurological processes Procalcitonin (PCT) is a typical biomarker for bacterial infections. since it increases in response to bacterial infections but not to other inflammatory reactions such as viral infections. Aim: study the role of IL-6 and PCT on renal failure that is affected by bacterial and viral infection. Methods: Between January and April 2023, 120 patients were confirmed to have chronic renal failure with or without diabetes mellitus who were affected or not via bacterial or viral infections based on previous medical reports and were divided into six groups; each of them included 20 patients. IL-6 and PCT levels were assayed and compared among groups. Different groups had very significantly different levels of IL-6 (90.40±25.77 for patients in G1, 42.33±17.32 for patients in G2, 84.95±19.80 for patients in G3, and 36.68±15.10 for patients in G4). The levels were 2.44±0.79 for patients in G5 and 2.26±0.59 for the control group, respectively (p<0.0001). The levels of PCT were also significantly different between groups (4.77±1.86 for patients in G1; 0.31±0.09 for patients in G2; 4.41±1.43 for patients in G3; 0.28±0.09 for patients in G4). The levels were 0.04±0.01 for patients in G5 and 0.03±0.01 for the control group, respectively (p<0.0001). Results: The findings demonstrated significant in levels of interleukin-6, urea, and creatinine in all patients except diabetic patients and significant increase in the level of procalcitonin in patients who have a bacterial infection, not a viral infection. Conclusion: The level of IL-6 increases in renal failure in both bacterial and viral infection states, but the Procalcitonin level increases in bacterial infection only.
- 20 February 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (1) , 461-468
Open AccessThe Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection
Background: IL-6 is one of the most studied cytokines in kidney disease. It is making inflammation worse by activating B cells that affect the production of hepatic acute phase proteins. It is also involved in metabolic, regenerative, and neurological processes Procalcitonin (PCT) is a typical biomarker for bacterial infections. since it increases in response to bacterial infections but not to other inflammatory reactions such as viral infections. Aim: study the role of IL-6 and PCT on renal failure that is affected by bacterial and viral infection. Methods: Between January and April 2023, 120 patients were confirmed to have chronic renal failure with or without diabetes mellitus who were affected or not via bacterial or viral infections based on previous medical reports and were divided into six groups; each of them included 20 patients. IL-6 and PCT levels were assayed and compared among groups. Different groups had very significantly different levels of IL-6 (90.40±25.77 for patients in G1, 42.33±17.32 for patients in G2, 84.95±19.80 for patients in G3, and 36.68±15.10 for patients in G4). The levels were 2.44±0.79 for patients in G5 and 2.26±0.59 for the control group, respectively (p<0.0001). The levels of PCT were also significantly different between groups (4.77±1.86 for patients in G1; 0.31±0.09 for patients in G2; 4.41±1.43 for patients in G3; 0.28±0.09 for patients in G4). The levels were 0.04±0.01 for patients in G5 and 0.03±0.01 for the control group, respectively (p<0.0001). Results: The findings demonstrated significant in levels of interleukin-6, urea, and creatinine in all patients except diabetic patients and significant increase in the level of procalcitonin in patients who have a bacterial infection, not a viral infection. Conclusion: The level of IL-6 increases in renal failure in both bacterial and viral infection states, but the Procalcitonin level increases in bacterial infection only.
- Open Access
- 2 April 2022
- Published by Universidad Tecnica de Manabi in International journal of health sciences
- p. 3075-3085
Measuring of D-dimer and other biochemical parameters as an early markers of severity in COVID-19 Patients with/without Diabetes Mellitus type II in Al Muthanna Province
Backgrounds: Since December 2019, when the coronavirus 2019 (Covid-19) first appeared in Wuhan and quickly spread throughout China, data on the clinical characteristics of the infected patients have been needed (Guan et al. 2020). Diabetes mellitus (DM) is a metabolic alteration characterized by chronic hyperglycemia. DM is considered one of the most common comorbidities in COVID-19 patients (Conget 2002). Aim: To identify the clinical variance between Covid-19 patients with and without DM (type II). Methods: The study contain 132 patients divided into four groups, there was 66 patients of them infected by COVID-19 with or without diabetic. The study was started from September 2021 to February 2022. Results: The results of the study appeared elevation the values of the most parameters measured for patients with/without diabetic such as D-dimer, ALT, AST, Blood Glucose, and Ferritin. But no change in Bilirubin and Alkaline phosphate (ALP). Conclusion: The COVID-19 patients with DM (type II) may be have the highest risk factors, which can increase the mortality, elevate the inflammation markers and affect the life enzymes (ALT, AST).
- 2 April 2022
- Published by Universidad Tecnica de Manabi in International journal of health sciences
- p. 3075-3085
Open AccessMeasuring of D-dimer and other biochemical parameters as an early markers of severity in COVID-19 Patients with/without Diabetes Mellitus type II in Al Muthanna Province
Backgrounds: Since December 2019, when the coronavirus 2019 (Covid-19) first appeared in Wuhan and quickly spread throughout China, data on the clinical characteristics of the infected patients have been needed (Guan et al. 2020). Diabetes mellitus (DM) is a metabolic alteration characterized by chronic hyperglycemia. DM is considered one of the most common comorbidities in COVID-19 patients (Conget 2002). Aim: To identify the clinical variance between Covid-19 patients with and without DM (type II). Methods: The study contain 132 patients divided into four groups, there was 66 patients of them infected by COVID-19 with or without diabetic. The study was started from September 2021 to February 2022. Results: The results of the study appeared elevation the values of the most parameters measured for patients with/without diabetic such as D-dimer, ALT, AST, Blood Glucose, and Ferritin. But no change in Bilirubin and Alkaline phosphate (ALP). Conclusion: The COVID-19 patients with DM (type II) may be have the highest risk factors, which can increase the mortality, elevate the inflammation markers and affect the life enzymes (ALT, AST).
- 1 September 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1858 (9) , 1999-2005
Two successive calcium-dependent transitions mediate membrane binding and oligomerization of daptomycin and the related antibiotic A54145
- 1 September 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1858 (9) , 1999-2005
Two successive calcium-dependent transitions mediate membrane binding and oligomerization of daptomycin and the related antibiotic A54145
- 1 October 2014
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1838 (10) , 2425-2430
Daptomycin forms cation- and size-selective pores in model membranes
- 1 October 2014
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1838 (10) , 2425-2430
Daptomycin forms cation- and size-selective pores in model membranes
- Open Access
- 1 April 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (17) , 11584-11591
Cardiolipin Prevents Membrane Translocation and Permeabilization by Daptomycin
- 1 April 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (17) , 11584-11591
Open AccessCardiolipin Prevents Membrane Translocation and Permeabilization by Daptomycin
- 1 February 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1828 (2) , 302-308
Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462
- 1 February 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1828 (2) , 302-308
Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462
- 31 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1818 (7) , 1642-1647
Estimation of the subunit stoichiometry of the membrane-associated daptomycin oligomer by FRET
- 31 July 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1818 (7) , 1642-1647
Estimation of the subunit stoichiometry of the membrane-associated daptomycin oligomer by FRET
- 1 April 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1808 (4) , 1154-1160
Oligomerization of daptomycin on membranes
- 1 April 2011
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1808 (4) , 1154-1160
Oligomerization of daptomycin on membranes